Literature DB >> 28654042

A Unified Methodological Framework for Vestibular Schwannoma Research.

Lukas D Landegger1, Jessica E Sagers2, Sonam Dilwali2, Takeshi Fujita3, Mehmet I Sahin3, Konstantina M Stankovic4.   

Abstract

Vestibular schwannomas are the most common neoplasms of the cerebellopontine angle, making up 6-8% percent of all intracranial growths. Though these tumors cause sensorineural hearing loss in up to 95% of affected individuals, the molecular mechanisms underlying this hearing loss remain elusive. This article outlines the steps established in our laboratory to facilitate the collection and processing of various primary human tissue samples for downstream research applications integral to the study of vestibular schwannomas. Specifically, this work describes a unified methodological framework for the collection, processing, and culture of Schwann and schwannoma cells from surgical samples. This is integrated with parallel processing steps now considered essential for current research: the collection of tumor and nerve secretions, the preservation of RNA and the extraction of protein from collected tissues, the fixation of tissue for the preparation of sections, and the exposure of primary human cells to adeno-associated viruses for application to gene therapy. Additionally, this work highlights the translabyrinthine surgical approach to collect this tumor as a unique opportunity to obtain human sensory epithelium from the inner ear and perilymph. Tips to improve experimental quality are provided and common pitfalls highlighted.

Entities:  

Mesh:

Year:  2017        PMID: 28654042      PMCID: PMC5608471          DOI: 10.3791/55827

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  34 in total

1.  True incidence of vestibular schwannoma?

Authors:  Sven-Eric Stangerup; Mirko Tos; Jens Thomsen; Per Caye-Thomasen
Journal:  Neurosurgery       Date:  2010-11       Impact factor: 4.654

2.  Vestibular schwannomas in the modern era: epidemiology, treatment trends, and disparities in management.

Authors:  Ranjith Babu; Richa Sharma; Jacob H Bagley; Jeffrey Hatef; Allan H Friedman; Cory Adamson
Journal:  J Neurosurg       Date:  2013-02-22       Impact factor: 5.115

3.  Proteome of human perilymph.

Authors:  Andrew C Lysaght; Shyan-Yuan Kao; Joao A Paulo; Saumil N Merchant; Hanno Steen; Konstantina M Stankovic
Journal:  J Proteome Res       Date:  2011-08-03       Impact factor: 4.466

4.  MicroRNA-21 overexpression contributes to vestibular schwannoma cell proliferation and survival.

Authors:  Joseph A Cioffi; Wei Ying Yue; Sabrina Mendolia-Loffredo; Kameron R Hansen; P Ashley Wackym; Marlan R Hansen
Journal:  Otol Neurotol       Date:  2010-12       Impact factor: 2.311

Review 5.  Management of sporadic vestibular schwannoma.

Authors:  Matthew L Carlson; Michael J Link; George B Wanna; Colin L W Driscoll
Journal:  Otolaryngol Clin North Am       Date:  2015-04-15       Impact factor: 3.346

6.  Current epidemiology and management trends in acoustic neuroma.

Authors:  Thomas J Gal; Jennifer Shinn; Bin Huang
Journal:  Otolaryngol Head Neck Surg       Date:  2010-05       Impact factor: 3.497

7.  In Silico Reconstruction of the Viral Evolutionary Lineage Yields a Potent Gene Therapy Vector.

Authors:  Eric Zinn; Simon Pacouret; Vadim Khaychuk; Heikki T Turunen; Livia S Carvalho; Eva Andres-Mateos; Samiksha Shah; Rajani Shelke; Anna C Maurer; Eva Plovie; Ru Xiao; Luk H Vandenberghe
Journal:  Cell Rep       Date:  2015-07-30       Impact factor: 9.423

8.  Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections.

Authors:  G Cattoretti; M H Becker; G Key; M Duchrow; C Schlüter; J Galle; J Gerdes
Journal:  J Pathol       Date:  1992-12       Impact factor: 7.996

9.  Primary culture of human vestibular schwannomas.

Authors:  Nathan M Schularick; J Jason Clark; Marlan R Hansen
Journal:  J Vis Exp       Date:  2014-07-20       Impact factor: 1.355

10.  Global profiling in vestibular schwannomas shows critical deregulation of microRNAs and upregulation in those included in chromosomal region 14q32.

Authors:  Miguel Torres-Martin; Luis Lassaletta; Jose M de Campos; Alberto Isla; Javier Gavilan; Giovanny R Pinto; Rommel R Burbano; Farida Latif; Barbara Melendez; Javier S Castresana; Juan A Rey
Journal:  PLoS One       Date:  2013-06-11       Impact factor: 3.240

View more
  4 in total

1.  Gene therapy with apoptosis-associated speck-like protein, a newly described schwannoma tumor suppressor, inhibits schwannoma growth in vivo.

Authors:  Sherif G Ahmed; Ahmed Abdelnabi; Casey A Maguire; Mohamed Doha; Jessica E Sagers; Rebecca M Lewis; Alona Muzikansky; Marco Giovannini; Anat Stemmer-Rachamimov; Konstantina M Stankovic; Giulia Fulci; Gary J Brenner
Journal:  Neuro Oncol       Date:  2019-07-11       Impact factor: 12.300

2.  Losartan prevents tumor-induced hearing loss and augments radiation efficacy in NF2 schwannoma rodent models.

Authors:  Limeng Wu; Sasa Vasilijic; Yao Sun; Jie Chen; Lukas D Landegger; Yanling Zhang; Wenjianlong Zhou; Jun Ren; Samuel Early; Zhenzhen Yin; William W Ho; Na Zhang; Xing Gao; Grace Y Lee; Meenal Datta; Jessica E Sagers; Alyssa Brown; Alona Muzikansky; Anat Stemmer-Rachamimov; Luo Zhang; Scott R Plotkin; Rakesh K Jain; Konstantina M Stankovic; Lei Xu
Journal:  Sci Transl Med       Date:  2021-07-14       Impact factor: 19.319

3.  Computational repositioning and preclinical validation of mifepristone for human vestibular schwannoma.

Authors:  Jessica E Sagers; Adam S Brown; Sasa Vasilijic; Rebecca M Lewis; Mehmet I Sahin; Lukas D Landegger; Roy H Perlis; Isaac S Kohane; D Bradley Welling; Chirag J Patel; Konstantina M Stankovic
Journal:  Sci Rep       Date:  2018-04-03       Impact factor: 4.379

4.  Tumor-Penetrating Delivery of siRNA against TNFα to Human Vestibular Schwannomas.

Authors:  Yin Ren; Jessica E Sagers; Lukas D Landegger; Sangeeta N Bhatia; Konstantina M Stankovic
Journal:  Sci Rep       Date:  2017-10-10       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.